CA2135203A1 - Metering Spray Designed for Pernasal Application - Google Patents

Metering Spray Designed for Pernasal Application

Info

Publication number
CA2135203A1
CA2135203A1 CA 2135203 CA2135203A CA2135203A1 CA 2135203 A1 CA2135203 A1 CA 2135203A1 CA 2135203 CA2135203 CA 2135203 CA 2135203 A CA2135203 A CA 2135203A CA 2135203 A1 CA2135203 A1 CA 2135203A1
Authority
CA
Canada
Prior art keywords
metering spray
pernasal application
designed
sex hormone
spray designed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2135203
Other languages
French (fr)
Other versions
CA2135203C (en
Inventor
Claudia Mattern
Rudiger Hakker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
M&P Patent AG
Original Assignee
Claudia Mattern
Rudiger Hakker
Arrowdean Limited
Cum Pharma Consulting Anstalt
M & P Patent Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Claudia Mattern, Rudiger Hakker, Arrowdean Limited, Cum Pharma Consulting Anstalt, M & P Patent Aktiengesellschaft filed Critical Claudia Mattern
Publication of CA2135203A1 publication Critical patent/CA2135203A1/en
Application granted granted Critical
Publication of CA2135203C publication Critical patent/CA2135203C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Abstract

Described is a metering spray designed for pernasal application, the spray containing at least one sex hormone or at least one metabolic precursor of a sex hormone or at least one derivative of a sex hormone or combinations of these, excepting the precursors of testosterone, or at least one biogenic amine, with the exception of catecholamines.
CA002135203A 1992-06-03 1993-05-17 Metering spray designed for pernasal application Expired - Lifetime CA2135203C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEP4218291.3 1992-06-03
DE19924218291 DE4218291A1 (en) 1992-06-03 1992-06-03 Dosing spray for pernasal application
PCT/DE1993/000442 WO1993024107A1 (en) 1992-06-03 1993-05-17 Metering spray designed for pernasal application

Publications (2)

Publication Number Publication Date
CA2135203A1 true CA2135203A1 (en) 1993-12-09
CA2135203C CA2135203C (en) 1998-12-29

Family

ID=6460299

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002135203A Expired - Lifetime CA2135203C (en) 1992-06-03 1993-05-17 Metering spray designed for pernasal application

Country Status (6)

Country Link
EP (1) EP0643575B1 (en)
JP (1) JP3705600B2 (en)
CA (1) CA2135203C (en)
DE (2) DE4218291A1 (en)
ES (1) ES2085775T3 (en)
WO (1) WO1993024107A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668114A (en) * 1996-05-08 1997-09-16 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating hypertension
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US5750512A (en) * 1995-01-17 1998-05-12 Birkmayer Pharmaceuticals, Inc. NADH and NADPH therapeutic agents for nasal, sublingual, rectal and dermal administration
US9186320B2 (en) 2006-10-04 2015-11-17 Mattern Pharma Ag Controlled release delivery system for nasal application of neurotransmitters
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US10111888B2 (en) 2011-05-13 2018-10-30 Acerus Biopharma Inc. Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US10668084B2 (en) 2011-05-13 2020-06-02 Acerus Biopharma Inc. Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US11090312B2 (en) 2013-03-15 2021-08-17 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1261501A (en) * 1999-12-06 2001-06-18 Stanley L. Gore Compositions and methods for intranasal delivery of active agents to the brain
US8652443B2 (en) 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6033M (en) 1967-02-10 1968-05-13
US4581225A (en) * 1984-04-25 1986-04-08 Eli Lilly And Company Sustained release intranasal formulation and method of use thereof
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
DE4003272A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg NEW GAS MIXTURES AND THEIR USE IN MEDICINE PREPARATIONS
CA2086096A1 (en) * 1990-06-27 1991-12-28 Robert A. Moris Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5116847A (en) * 1991-01-25 1992-05-26 The Procter & Gamble Company Use of loperamide and related compounds for treatment of respiratory disease symptoms
DE4214953C2 (en) * 1992-05-06 1995-05-18 Arrowdean Ltd Medicines to increase testosterone levels

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750512A (en) * 1995-01-17 1998-05-12 Birkmayer Pharmaceuticals, Inc. NADH and NADPH therapeutic agents for nasal, sublingual, rectal and dermal administration
US5952312A (en) * 1995-01-17 1999-09-14 Birkmayer Pharmaceuticals, Inc. NADH and NADPH therapeutic agents for nasal, sublingual, rectal and dermal administration
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US5668114A (en) * 1996-05-08 1997-09-16 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating hypertension
US9186320B2 (en) 2006-10-04 2015-11-17 Mattern Pharma Ag Controlled release delivery system for nasal application of neurotransmitters
US9801834B2 (en) 2006-10-04 2017-10-31 M et P Pharma AG Controlled release delivery system for nasal application of neurotransmitters
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US10111888B2 (en) 2011-05-13 2018-10-30 Acerus Biopharma Inc. Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US10668084B2 (en) 2011-05-13 2020-06-02 Acerus Biopharma Inc. Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US11090312B2 (en) 2013-03-15 2021-08-17 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event

Also Published As

Publication number Publication date
CA2135203C (en) 1998-12-29
DE59301810D1 (en) 1996-04-11
JPH07507279A (en) 1995-08-10
EP0643575A1 (en) 1995-03-22
JP3705600B2 (en) 2005-10-12
DE4218291A1 (en) 1993-12-09
ES2085775T3 (en) 1996-06-01
WO1993024107A1 (en) 1993-12-09
EP0643575B1 (en) 1996-03-06

Similar Documents

Publication Publication Date Title
EP1193270A3 (en) Pyrrolobenzodiazepines
CA2216169A1 (en) Use of compositions comprising stabilized biologically effective compounds
BR9809189A (en) Compounds suitable for controlled release of the gnrh hormone and its analogs
CA2135203A1 (en) Metering Spray Designed for Pernasal Application
AU6613896A (en) Chemical compounds
HK1049657A1 (en) Imine intermediates for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties
IL129848A (en) Coated particles and methods of making and using same
ATE180773T1 (en) N-SULFONYL-2-OXOINDOLE DERIVATIVES WITH AN AFFINITY FOR THE VASOPRESSIN AND/OR OCYTOCIN RECEPTORS
CA2263913A1 (en) Substituted 6,6-hetero-bicyclic derivatives
CA2146852A1 (en) New substituted pyrazole derivatives, processes for their preparation and their use as herbicides
AU6866291A (en) Pharmacologically active compounds and mixtures thereof, organic compositions and metal salts
AU4064597A (en) Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
AU3387293A (en) Improvements in or relating to organic compounds
YU41199A (en) Quinoxalinediones
CA2245267A1 (en) Crystal form of n-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
CA2309277A1 (en) Concentrate dosing device for refillable spray dispensers
CA2118030A1 (en) Drug for increasing the level of testosterone in the body
AU1238100A (en) Topical vitamin composition
CA2352392A1 (en) Eletriptan hydrobromide monohydrate
CA2094424A1 (en) Method of treating osteoporosis with 1.alpha.,24(r)-dihydroxy-22(e)-dehydro-vitamin d3
EP0620237A3 (en) Two-component coating composition for the preparation of PUR-elastomers.
EP0757032A3 (en) Naphthalene compound, and liquid crystal composition and liquid crystal element using the same
BG105862A (en) Light, extruded compositions containing a light, extrudable, ceramic carrier, methods for their use and preparartion
ITTO910541A1 (en) WATERPROOFING COATING, PARTICULARLY FOR THE ELIMINATION OF INFILTRATION

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130517

MKEC Expiry (correction)

Effective date: 20131009